ProQR Therapeutics (PRQR) announced Wednesday morning that its Phase 1/2 trial of QR-110 in patients with Leber's congenital amaurosis 10 demonstrated rapid and sustained improvement in vision. The company announced plans to progress to a Phase 2/3 trial.
from RTT - Hot Stocks https://ift.tt/2PGgZWm
via IFTTT
No comments:
Post a Comment